In particular, we employed the pan-RAF inhibitor LY3009120 (Supplementary Fig. 5a) as its antitumor activity has been successfully shown in in vivo BRAFmut and KRASmut colorectal cancer xenograft models [23]. Here, RAF1 is linked to colorectal cancer.